Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity

References

• An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y. 2012. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 39(6):535–543.
   PubMed Web of Science ®Google Scholar
• Andrews E, Armstrong M, Tugwood J, Swan D, Glaves P, Pirmohamed M, Aithal GP, Wright MC, Day CP, Daly AK. 2010. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology. 51(5):1656–1664.
   PubMed Web of Science ®Google Scholar
• Arand M, Muhlbauer R, Hengstler J, Jager E, Fuchs J, Winkler L, Oesch F. 1996. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem. 236(1):184–186.
   PubMed Web of Science ®Google Scholar
• Chen R, Wang J, Zhang Y, Tang S, Zhan S. 2015. Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity. Arch Toxicol. 89(6):883–897.
   PubMed Web of Science ®Google Scholar
• Danan G, Teschke R. 2015. RUCAM in drug and herb induced liver injury: the update. IJMS. 17(1):14.
   Web of Science ®Google Scholar
• He L, Guo Y, Deng Y, Li C, Zuo C, Peng W. 2017. Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin. Xenobiotica. 47(2):154–163.
   PubMed Web of Science ®Google Scholar
• Hein DW, Doll MA. 2012. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. PHARMACOGENOMICS. 13(1):31–41.
   PubMed Web of Science ®Google Scholar
• Huang Y, Su W, Huang Y, Chen C, Chang F, Lin H, Lee S. 2007. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S -transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol. 47(1):128–134.
   PubMed Web of Science ®Google Scholar
• Hussain Z, Zhu J, Ma X. 2021. Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug. Drug Metab Dispos. 49(8):679–682.
   PubMed Web of Science ®Google Scholar
• Klein DJ, Boukouvala S, McDonagh EM, Shuldiner SR, Laurieri N, Thorn CF, Altman RB, Klein TE. 2016. PharmGKB summary: isoniazid pathway, pharmacokinetics. Pharmacogenet Genomics. 26(9):436–444.
   PubMed Web of Science ®Google Scholar
• Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, Klaassen CD, Gonzalez FJ, Ma X. 2013. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med. 19(4):418–420.
   PubMed Web of Science ®Google Scholar
• Lu L, Tao B, Wei H, Chen H, He X, Pan H, Yang M, Yi H, Tang S. 2019. Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population. J Gene Med. 21(6):e3096.
   PubMed Web of Science ®Google Scholar
• Moore JT, Moore LB, Maglich JM, Kliewer SA. 2003. Functional and structural comparison of PXR and CAR. Biochim Biophys Acta. 1619(3):235–238.
   PubMed Web of Science ®Google Scholar
• Preziosi P. 2007. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab. 8(8):839–851.
   PubMed Web of Science ®Google Scholar
• Nagarajan S, Whitaker P. 2018. Management of adverse reactions to first-line tuberculosis antibiotics. Curr Opin Allergy Clin Immunol. 18(4):333–341.
   PubMed Web of Science ®Google Scholar
• Ramappa V, Aithal GP. 2013. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 3(1):37–49.
   PubMedGoogle Scholar
• Rana M, Coshic P, Goswami R, Tyagi RK. 2017. Influence of a critical single nucleotide polymorphism on nuclear receptor PXR-promoter function. Cell Biol Int. 41(5):570–576.
   PubMed Web of Science ®Google Scholar
• Richardson M, Kirkham J, Dwan K, Sloan DJ, Davies G, Jorgensen AL. 2019. NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 23(3):293–305.
   PubMed Web of Science ®Google Scholar
• Sahu RK, Singh K, Subodh S. 2015. Adverse drug reactions to anti-TB drugs: pharmacogenomics perspective for identification of host genetic markers. Curr Drug Metab. 16(7):538–552.
   PubMed Web of Science ®Google Scholar
• Shehu AI, Ma X. 2018. Pregnane X receptor in drug-induced liver injury: friend or foe? Liver Research. 2(4):173–179.
   Google Scholar
• Stephens M, Donnelly P. 2003. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 73(5):1162–1169.
   PubMed Web of Science ®Google Scholar
• Stephens M, Scheet P. 2005. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet. 76(3):449–462.
   PubMed Web of Science ®Google Scholar
• Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 68(4):978–989.
   PubMed Web of Science ®Google Scholar
• Sun Q, Liu HP, Zheng RJ, Wang P, Liu ZB, Sha W, Xiao HP. 2017. Genetic polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and susceptibility to anti-tuberculosis drug-induced hepatotoxicity: a Chinese population-based prospective case-control study. Clin Drug Investig. 37(12):1125–1136.
   PubMed Web of Science ®Google Scholar
• Tuberculosis Branch of Chinese Medical Association. 2019. [Guidelines for the diagnosis and treatment of antituberculous drug-induced liver injury (2019 edition)]. Chin J Tuberc Respiration. 42(5):343–356.
   Google Scholar
• Wang J, Bwayi M, Gee R, Chen T. 2020. PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches. Expert Opin Drug Metab Toxicol. 16(8):711–722.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiang X, Huang WW, Sandford AJ, Wu SQ, Zhang MM, Wang MG, Chen G, He JQ. 2019. Association of PXR and CAR polymorphisms and antituberculosis drug-induced hepatotoxicity. Sci Rep. 9(1):2217.
   PubMed Web of Science ®Google Scholar
• World Health Organization 2021. Global tuberculosis report 2021. Geneva: WHO.
   Google Scholar
• Yang M, Qiu Y, Jin Y, Liu W, Wang Q, Yi H, Tang S. 2020. NR1I2 genetic polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity: a systematic review and meta-analysis. Pharmacol Res Perspect. 8(6):e696.
   Web of Science ®Google Scholar
• Yang S, Hwang SJ, Park JY, Chung EK, Lee JI. 2019. Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. BMJ Open. 9(8):e27940.
   Web of Science ®Google Scholar
• Yew WW, Chang KC, Chan DP. 2018. Oxidative stress and first-line antituberculosis drug-induced hepatotoxicity. Antimicrob Agents Chemother. 62(8):e02637–17.
   PubMed Web of Science ®Google Scholar
• Zazuli Z, Barliana MI, Mulyani UA, Perwitasari DA, Ng H, Abdulah R. 2015. Polymorphism of PXR gene associated with the increased risk of drug-induced liver injury in Indonesian pulmonary tuberculosis patients. J Clin Pharm Ther. 40(6):680–684.
   PubMed Web of Science ®Google Scholar
• Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, et al. 2001. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 11(7):555–572.
   PubMedGoogle Scholar
• Zhang J, Zhao Z, Bai H, Wang M, Jiao L, Peng W, Wu T, Liu T, Chen H, Song X, et al. 2019a. Genetic polymorphisms in PXR and NF-kappaB1 influence susceptibility to anti-tuberculosis drug-induced liver injury. Plos One. 14(9):e222033.
   Web of Science ®Google Scholar
• Zhang M, Wu SQ, He JQ. 2019b. Are genetic variations in glutathione S-transferases involved in anti-tuberculosis drug-induced liver injury? A meta-analysis. J Clin Pharm Ther. 44(6):844–857.
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang S, Wilffert B, Tong R, van Soolingen D, van den Hof S, Alffenaar JW. 2018. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br J Clin Pharmacol. 84(12):2747–2760.
   PubMed Web of Science ®Google Scholar